logo-loader
ReNeuron Group PLC

ReNeuron 'very encouraged' by positive retinitis pigmentosa study results

ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott after announcing that the first group of patients receiving cell therapy for a blindness-causing disease saw “sustained and further improvement” to their sight.

The data's from a phase IIa study of their human retinal progenitor cell (hRPC) treatment for retinitis pigmentosa.

Quick facts: ReNeuron Group PLC

Price: £2.11

Market: LSE
Market Cap: £67.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Asiamet signs agreement with China Nonferrous Metals

Headlines from the Proactive UK newsroom. Asiamet (LON:ARS) has teamed up with China Nonferrous Metals to carry out an engineering evaluation on the BKM Copper project in Indonesia.  China NFC is currently building a zinc mine in Sumatra and is looking to expand its activities in the...

2 days, 20 hours ago

2 min read